Low PCDH7 immunoexpression has been associated with high pathological grade, recurrence, and tumor progression; this fact is an independent prognostic factor for clinical outcome (Lin et al., 2016) and is associated with BC invasiveness (Ma et al., 2013). Here, PCDH7 is linked to neoplasm.